Posted Sun, Feb, 21,2016
This author interview is by Dr. Noel Pabalan, of Angeles University Foundation. Dr. Pabalan's full paper, Associations of the A66G Methionine Synthase Reductase (MTRR) Polymorphism in Colorectal Cancer: A Systematic Review and Meta-Analysis, is available for download in Biomarkers in Cancer.
Please summarize for readers the content of your article.
Associations between A66G polymorphism in the methionine synthase reductase (MTRR) and colorectal cancer are meta-analyzed. Overall findings showed no evidence of associations. However, modifier analyses indicated significant protective associations. This shows the utility of the meta-analytic treatment in uncovering associations which may have not been previously observed.
How did you come to be involved in your area of study?
I was requested by the guest editor, Dr. Sevtap Savas of the Memorial University of Newfoundland to contribute an article to Biomarkers. My long experience in doing meta-analysis allowed for quick research on potential meta-analyzable polymorphisms for colorectal cancer.
What was previously known about the topic of your article?
Since meta-analysis is dynamic, associations are continually modified to accommodate new knowledge. Two previous meta-analysis have been published on this topic. One paper found no associations but the other did, in the Caucasian subgroup. With updated information, our meta-analysis found no Caucasian associations, but did among Asians.
How has your work in this area advanced understanding of the topic?
Our work advanced understanding of the topic in a way that incorporated new information, performing rigorous meta-analysis and deriving new conclusions on the topic.
What do you regard as being the most important aspect of the results reported in the article?
MTRR A66G posed susceptibility for Asians but not Caucasians. However, modifier analyses uncovered significant protective effects of this polymorphism against colorectal cancer.
Posted in: Authors
Tue 17 Jan, 2017Public Science Insights: A molecular perspective of clinical benefit: Why shouldn't Luminal-A patients be considered in pCR discussions?
Wed 11 Jan, 2017Recently Published (26th December – 6th January)
Fri 06 Jan, 2017Published During December
The process of submission and publishing was a great experience. During the few weeks from the submission to publication I have worked with high quality staff. In my opinion, the easy communication was the most important characteristic of the joural and an important influence on the final quality of the article. I definitely recommend the publisher to my colleagues.